https://www.dcatvci.org/top-industry-news/takeda-tigenix-sign-400-million-plus-deal-for-crohn-s-disease-drug/
Takeda, TiGenix Sign $400-Million Plus Deal For Crohn's Disease Drug - DCAT Value Chain Insights
Sep 8, 2021 - Takeda Pharmaceutical Company and TiGenix NV, a Belgian biopharmaceutical company, have entered into an exclusive ex-US license, development, and...